Abstract m6A (N6-methyladenosine) methylation, a well-known modification in tumour
epigenetics, dynamically and reversibly fine tunes the entire process of RNA metabolism …

Background Ovarian cancer is the leading cause of cancer-related death among
gynecologic malignancies. With much evidence suggesting that 18F-FDG PET/CT may be …

Purpose To provide an organized, international, state-of-the-art, and multidisciplinary
guideline, led by experts of two nuclear medicine societies (EANM and SNMMI) and …

Purpose To compare the efficacy of [68Ga] Ga-FAPI-04 PET/CT in primary or recurrent
tumors and metastatic lesions of epithelial ovarian cancer (EOC) with that of fluorine-18 …

Gynecologic malignancies, consisting of endometrial, cervical, ovarian, vulvar, and vaginal
cancers, pose significant diagnostic and management challenges due to their complex …

Integrating clinical and pathological data together with imaging-derived information, such as
radiomics and sarcopenia status, creating new combined biomarkers that increase the …

Ovarian cancer poses a major worldwide health issue, marked by high death rates and a
deficiency in reliable diagnostic methods. The precise and prompt detection of ovarian …

Abstract Studies with [68 Ga] Ga-labeled or [18 F] F-labeled fibroblast activation protein
inhibitor compounds have demonstrated favorable characteristics for PET/CT imaging …

Epithelial ovarian cancer most commonly presents at advanced stages, and prognosis is
influenced by residual disease following cytoreduction. The significance of cardiophrenic …

Ovarian cancer is usually diagnosed at advanced stages. Because of this, prognosis is poor.
More than two thirds of patients relapse after initial treatment. The peritoneum is 1 of the …